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Objectives: Previous studies into the survival differences between individuals with idiopathic
pulmonary fibrosis and those with connective tissue disease associated pulmonary fibrosis
(CTD-PF) have yielded mixed results. The aim of this study is to compare the survival of indi-
viduals with CTD-PF to those with idiopathic pulmonary fibrosis clinical syndrome (IPF-CS) using
data derived from The Health Improvement network, a large primary care database in the UK.
Methods: Incident cases of CTD-PF and IPF-CS between the years 2000e2009 were identified.
Survival analysis was performed using KaplaneMeier methods, stratified by type of connective
tissue disease. Cox regression was then used to compare mortality rates between the groups,
adjusting for age, gender and year of diagnosis.
Results: A total of 324 cases of CTD-PF and 2209 cases of IPF-CS were followed up over a mean
period of 2.3 years. During this period, 113 (34.9%) cases of CTD-PF and 1073 (48.6%) cases of
IPF-CS died. The mortality rates for cases with CTD-PF and IPF-CS were 123.6 per 1000 person
years (95%CI: 102.8e148.9) and 229.8 per 1000 person years (95% CI: 216.4e244.0) respec-
tively. After adjusting for age, sex and year of diagnosis, cases with CTD-PF had a better prog-
nosis compared to those with IPF-CS (HR 0.76,95%CI: 0.62e0.92).
Conclusion: The prognosis of individuals with CTD-PF appears to be significantly better than
those with IPF-CS, but remains an important cause of death in patients with connective tissue
disease, and requires more effective treatment options.
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The pulmonary complications that are associated with
connective tissue diseases are well recognised, but the
clinical course of pulmonary fibrosis that accompanies this
group of diseases is unclear. Despite these uncertainties, it
is acknowledged that pulmonary fibrosis associated with
connective tissue diseases is an important and serious
complication that can be under-recognised. This is partic-
ularly true with rheumatoid arthritis, the commonest type
of connective tissue disease, whereby almost 20% of indi-
viduals seen in hospital with this type of connective tissue
disease will have some evidence of pulmonary fibrosis on
high resolution computed tomography (HRCT).1
For a long time, patients with connective tissue disease
associated pulmonary fibrosis (CTD-PF) were thought to be
identical to those with cryptogenic fibrosing alveolitis (CFA)
as they had similar radiological and histopathological
patterns.2,3 This resulted in both groups of patients being
managed in the same fashion. There is now increased
recognition that the underlying histology of lung fibrosis
associated with connective tissue disease may vary from
that of idiopathic pulmonary fibrosis (IPF), particularly in
those individuals with scleroderma associated pulmonary
fibrosis. This has resulted in individuals with CTD-PF being
excluded from clinical trials involving cases with IPF, on the
argument that individuals with CTD-PF suffer from
a different disease entity, and hence should not be treated
in the same way as individuals with IPF.
It is currently uncertain if there is a difference in survival
between individuals with CTD-PF compared to those with IPF
as studies in to the subject so far have yielded varying
results.4e7 We have previously looked at the differences in
survival between cases of CTD-PF and cases with CFA using
primary care data, which showed little difference in median
survival between the two groups.7 A significant time period
has passed since our study, and with the reclassification of
interstitial lung diseases, we have revisited the same ques-
tion to re-evaluate the burden and outcome of recognised
disease among individuals with CTD-PF.
The aim of this study is to compare the survival of
individuals with idiopathic pulmonary fibrosis clinical
syndrome (IPF-CS) to those with connective tissue disease
associated pulmonary fibrosis (CTD-PF) using data from
a large general practice database.
Methods
The dataset used in this study was extracted from The
Health Improvement Network (THIN) which is a large com-
puterised primary care database in the United Kingdom.
Information is recorded as part of routine clinical care,
after face to face consultations and following communica-
tion with secondary care referrals. THIN has previously
been used to estimate incidence and mortality rates of
idiopathic pulmonary fibrosis.8,9 The version of THIN used in
this study includes all information available until July 2009
from 446 general practices.
We identified all individuals who had a new diagnosis of
pulmonary fibrosis made after the 1st of January 2000.
Cases were included into our cohort if they had at least onerecorded diagnosis of pulmonary fibrosis, the first recorded
diagnosis was at least 12 months after their practice
registration date and they were at least 40 years of age.
This definition enabled us to capture incident cases of
pulmonary fibrosis and the age cut off improved diagnostic
specificity. We excluded individuals with a coexisting
diagnosis of extrinsic allergic alveolitis, sarcoidosis, pneu-
moconiosis and asbestosis (see Appendix 1), because it is
not clear in this subset which diagnosis was correct, and
this approach provided a more conservative estimate of
disease mortality rates. Individuals with pulmonary fibrosis
and a coexisting diagnosis of connective tissue disease
(Rheumatoid Arthritis/Systemic Sclerosis/Systemic Lupus
Erythematosus/Polymyositis/Dermatomyositis/Mixed Conn-
ective Tissue Disease) were defined as having connective
tissue disease associated pulmonary fibrosis (CTD-PF) (see
Appendix 2). Individuals with pulmonary fibrosis and
without a coexistent diagnosis of connective tissue disease
were defined as having idiopathic pulmonary fibrosis clin-
ical syndrome (IPF-CS). The data were grouped into five-
year age bands over the age of 55 years.
All cases of pulmonary fibrosis were assigned a start date
which was defined as the date of diagnosis, and a stop date
that was defined as the earliest of either last date of data
collection within THIN or date of death. We initially
compared survival between cases with IPF-CS and CTD-PF,
and then repeated the analysis, stratifying cases of CTD-PF
by type of connective tissue disease using KaplaneMeir
methods. We used Cox regression modelling to compare
survival between cases with IPF-CS and CTD-PF and then
repeated the analysis, stratifying cases of CTD-PF by type
of connective tissue disease, adjusting for year of diag-
nosis, age categories and gender.
Stata version 11 (Texas) was used for all statistical
analyses and likelihood ratio tests for all hypotheses
testing.Results
The total number of incident cases of pulmonary fibrosis
over the study period was 2533, of which 324 (13%) had
a coexistent diagnosis of connective tissue disease. Within
this subset of connective tissue disease associated pulmo-
nary fibrosis (CTD-PF), rheumatoid arthritis (8.4%) and
scleroderma/systemic sclerosis (1.6%) were the most
common coexistent diagnoses (see Table 1). Cases with
CTD-PF were predominantly female compared to cases with
idiopathic pulmonary fibrosis clinical syndrome (IPF-CS)
(56.5 vs 37.1%; chi squared test p < 0.0001). Cases with
CTD-PF were also younger at time of diagnosis compared to
those with IPF (mean age at time of diagnosis 68 years vs 74
years, t test p < 0.0001).
The mean follow up period after diagnosis was 2.3 years
and during this period 1073 (48.6%) of cases with IPF-CS and
113 (34.9%) of all cases with CTD-PF died. This equates to
an overall crude mortality rate of 229.8 per 1000 person
years (95% Confidence Interval: 216.4e244.0) in individuals
with IPF-CS and 123.6 per 1000 person years (95% Confi-
dence Interval: 102.8e148.7) for all cases with CTD-PF (see
Table 2 for mortality rates stratified by type of connective
tissue disease).
Table 1 Demographics of incident cases of pulmonary fibrosis in The Health Improvement Network dataset.
Connective tissue disease Cases
(n Z 2533)
Mean age (years) at time of
diagnosis (standard deviation)
Percentage of cases
that are female
None 2209 (87.2%) 74.4 (10.1) 37.1%
Rheumatoid arthritis 213 (8.4%) 69.7 (9.2) 51.2%
Scleroderma/Systemic sclerosis 40 (1.6%) 61.8 (11.1) 75.0%
Other (SLE, dermatomyositis, polymyositis,
mixed connective tissue disease)
71 (2.8%) 66.2 (10.7) 62.0%
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mately 3.1 years compared to 6.5 years in cases with CTD-PF.
This difference in survival was statistically significant
(pZ 0.0043) (see Fig. 1). Using Cox regression modelling, we
found that after adjustment for age, sex and year of diag-
nosis, the presence of connective tissue disease had a bene-
ficial effect on mortality in individuals with pulmonary
fibrosis (Hazard Ratio 0.76, 95% Confidence Interval:
0.62e0.92). This reduction in mortality was still evident
when the analysis was repeated, stratifying those with CTD-
PF by type of connective tissue disease. (see Table 2, Fig. 2).
Discussion
Using data from primary care, we found a significant
difference in survival between individuals with idiopathic
pulmonary fibrosis clinical syndrome (IPF-CS) and those
with connective tissue disease associated pulmonary
fibrosis (CTD-PF), after adjusting for age, year of diagnosis
and sex. We have also found that the presence of connec-
tive tissue disease is more common among individuals with
pulmonary fibrosis within our current dataset (13%) in
comparison to the primary care dataset used in our previous
study (10%) ten years ago.7
One of the strengths of our study is the large number of
cases included into our dataset and the long period of
time over which this information was obtained. This
allows us to give a detailed analysis of mortality rates and
median survival stratified by type of connective tissue
disease. Studies of this length and magnitude would be
difficult to conduct in a clinical setting. Historically,
studies into pulmonary fibrosis associated with connective
tissue disease are conducted in tertiary referral centres
and have only small numbers of cases included in the
dataset.1,4,10Table 2 Mortality rates and Cox regression modelling in individ
tissue disease.
Connective tissue disease Number of
deaths
Person
years
Mort
1000
None 1073 4669.6 229.
Rheumatoid arthritis 75 564.5 132.
Scleroderma/Systemic sclerosis 9 126.9 70.
Other (SLE, dermatomyositis,
polymyositis, mixed
connective tissue disease)
29 222.5 130.
a Hazards ratios adjusted for year of diagnosis, age and gender.
b p value for likelihood ratio test.A potential weakness of the study is the validity of
diagnoses of pulmonary fibrosis and connective tissue
disease in our dataset. We have previously shown the
diagnosis of pulmonary fibrosis in primary care data to be
valid.8,11,12 We acknowledge that cases within our dataset
are likely to represent the full spectrum of chronic fibrotic
lung disease of unknown aetiology, the majority of which
will have idiopathic pulmonary fibrosis. For this reason, we
think it is more appropriate to label these individuals as
having idiopathic pulmonary fibrosis clinical syndrome (IPF-
CS). We also believe that it is unlikely for an individual to
have a diagnosis of pulmonary fibrosis recorded in primary
care without confirmation from a specialist secondary
opinion. Further reassurance of the diagnostic validity of
pulmonary fibrosis is demonstrated by the fact that the
median survival of individuals with IPF-CS in this study is
similar to other population based studies.12e15 We believe
the same high validity applies for the diagnosis of connec-
tive tissue disease within our dataset. Although we have not
formally validated the diagnosis of connective tissue
disease within this dataset, we are reassured by previous
studies that have demonstrated high validity of a recorded
diagnosis of connective tissue disease in the General Prac-
tice Research Database (GPRD),16,17 a computerised
primary care database in the United Kingdom that is similar
to The Health Improvement Network (THIN). Both data-
bases record patient information and code data in a similar
fashion, and hence we would expect the same high validity
of recording shown in GPRD to apply to THIN. In addition to
this, we also believe that a diagnosis of connective tissue
disease would typically be established by a rheumatologist
and it is unlikely that such a diagnosis would be recorded
without confirmation from secondary or tertiary care.
Another potential weakness is the potential overlap
between the different types of connective tissue disease. Ituals with pulmonary fibrosis stratified by type of connective
ality rate (95%CI)per
person years
Hazard
ratioa (95% CI)
Median
survival (years)
8 (216.4e244.0) 1.0 3.1
9 (106.0e166.6) 0.75 (0.59e0.96) 6.6
9 (36.9e136.3) 0.55 (0.28e1.06) 8.8
3 (90.6e187.5) 0.86 (0.59e1.25)
bp Z 0.019
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Figure 1 KaplaneMeir plot of survival among cases of idio-
pathic pulmonary fibrosis clinical syndrome (IPF-CS) compared
to cases of connective tissue disease associated pulmonary
fibrosis (CTD-PF).
1928 V. Navaratnam et al.has been observed in clinical practice that individuals can
move between the different subtypes of connective tissue
disease or have their diagnosis altered after an initial
prodrome. The overall aim of our study was to investigate
the difference in survival between individuals with IPF-CS
and those with CTD-PF and to see if any difference in
survival was altered after stratification by type of under-
lying connective tissue disease. Hence, any misclassifica-
tion in the subtype of connective tissue disease associated
with pulmonary fibrosis is unlikely to alter our findings. We
are also unable to exclude the possibility that a small
number of cases within our CTD-PF subset may have
pulmonary fibrosis secondary to treatment received for the
underlying connective tissue disease. However, this does
not change our conclusion that individuals with pulmonary
fibrosis associated with connective tissue disease have
a better prognosis compared to those who do not have
a coexisting diagnosis of CTD.
There is limited data available on median lengths of
survival stratified by type of connective tissue disease. We0.
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Figure 2 KaplaneMeir plot of survival amongst cases of
pulmonary fibrosis stratified by type of underlying connective
tissue disease.have previously looked at the differences in survival
between cases with lone cryptogenic fibrosing alveolitis
(CFA) and cases with connective tissue disease associated
fibrosing alveolitis (FA-CTD) using data from primary care.7
The previous study showed no difference in survival
between the two groups (median survival 2.6 years vs 2.4
years). The overall prevalence of connective tissue disease
in our current dataset is slightly higher at 13% compared to
10% in our previous cohort of cases. This raises the possi-
bility that the difference in survival could be due to
increased case ascertainment and in individuals with
connective tissue disease, due to increased recognition of
pulmonary fibrosis by rheumatologists. The introduction of
a multidisciplinary approach to the management of
patients with connective tissue disease has resulted in
rheumatologists being more aware of the pulmonary
complications that can occur. It is also more common for
patients with connective tissue disease to undergo baseline
radiological investigations prior to commencing disease
modifying treatment, as many of these drugs have toxic
pulmonary side effects. The widespread use of high reso-
lution computed tomography scans (HRCT) to aid the
diagnosis of suspected interstitial lung disease raises the
possibility that milder cases of pulmonary fibrosis are being
identified within the CTD-PF group. If milder cases of
pulmonary fibrosis are being diagnosed in the CTD-PF
group, this would offer an explanation as to why we have
found a difference in survival within this cohort when
previously there was no significant difference in survival.
Previous studies done to date on the potential differ-
ences in survival have yielded mixed results and one of the
limitations is that most of them have only a small numbers
of patients. A study in Newcastle followed up patients with
rheumatoid arthritis associated interstitial lung disease(RA-
ILD) and with cryptogenic fibrosing alveolitis over 5 years
and found that median survival was significantly longer in
the RA-ILD group.4 This differs from the findings of Early
Rheumatoid Arthritis Study (ERAS) who reported a median
survival of 3 years following a diagnosis of RA-ILD within
their cohort. This median survival is similar to reported
lengths of survival within IPF cohorts.5
Studies have consistently shown that the prognosis of
pulmonary fibrosis associated with systemic sclerosis or
scleroderma is better than other connective tissue diseases,
and certainly better compared to IPF, and our findings in this
study confirmthis.10,18 It has been speculated that the reason
behind this difference in survival either stems from lead time
bias or that pulmonary fibrosis secondary to scleroderma is
a completely different disease entity to IPF. In a study con-
ducted in the Brompton Hospital, researchers matched
patients with lone CFA and those with scleroderma associ-
ated pulmonary fibrosis on the basis of CT scans to try and
remove the problem of lead time bias.18 They found that the
cases with scleroderma associated lung fibrosis had a better
outcome compared to those with lone CFA.18 It has been
established that the predominant histopathological pattern
in patients with scleroderma associated pulmonary fibrosis is
non-specific interstitial pneumonia (NSIP)19 which may have
a better prognosis. In comparison, themajority of cases with
pulmonary fibrosis associated with rheumatoid arthritis have
been shown to have a usual interstitial pneumonia (UIP),20
similar to the histopathological pattern found in IPF. The
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nostic factor in patients with rheumatoid arthritis associated
pulmonary fibrosis remains unclear. Recently, a study among
patients with rheumatoid arthritis associated interstitial
lung disease reported that the survival between patients
with rheumatoid arthritis and a definite UIP pattern on their
HRCT was worse in comparison to those with a non-UIP
pattern.6 The same study also suggested that the survival
between the rheumatoid arthritis UIP cases was similar to
patients with idiopathic pulmonary fibrosis. These findings
are different to those reported by Park and colleagues who
found that the prognosis of patients with connective tissue
disease and a UIP histopathological pattern was better
compared to those with IPF.21
In summary, our study suggests that individuals with
connective tissue disease pulmonary fibrosis (CTD-PF) have
a better prognosis than individuals with idiopathic pulmo-
nary fibrosis clinical syndrome (IPF-CS). This could be due
to the fact that interstitial lung disease is now increasingly
recognised as a complication of connective tissue disease
and hence milder cases of pulmonary fibrosis are being
diagnosed. The fact remains that both groups of patients
have a considerable burden of morbidity and mortality in
comparison to the general population. Aside from cyclo-
phosphamide, which has been shown to have some modest
effect on lung function and symptoms in patients with
scleroderma,22 there are no other disease modifying drugs
that have been proven effective in treating this subgroup of
patients. Given the fact that individuals with CTD-PF are
now excluded from clinical trials involving patients with
IPF, it is necessary to push forward in closing the gaps in our
knowledge between these two groups of patients so we can
understand how best to manage them.
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